A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19 Pandemic
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- Seroconvension of SARS-CoV-2 neutralizing antibodies
- Last Updated
- 4 years ago
Overview
Brief Summary
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Detailed Description
This is a single arm, open-label clinical study. 45 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines will be enrolled in this study to evaluate the safety and immunogenicity of V-01. The participants will be collected blood before immunization, on day 7, day 14, day 28 and 6 month to evaluate humoral immunity. All adverse events (AEs) within 30 minutes and 0-7 days after booster immunization, and unsolicited AEs from 8 to 28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization will be collected from all participants.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants aged 18 years and older who have completed the second dose of 2-dose regimen of inactive vaccination (Vero cell) against SARS-CoV-2 in the past 3-6 months;
- •Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
- •In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
- •Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.
Exclusion Criteria
- •Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR.
- •History of previous COVID-19 infection.
- •Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.
- •History of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of V-
- •People who currently suffer from the following diseases:
- •Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
- •Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
- •Patients with congenital or acquired angioedema/neuroedema;
- •A history of congenital or acquired immunodeficiency or autoimmune disease (except for mild psoriasis, controllable autoimmune thyroid disease, vitiligo, or stable celiac disease that does not require immunosuppressive or immunomodulatory therapy); no spleen , or history of spleen surgery, history of trauma, or treatment with immunomodulators within 6 months, such as: glucocorticoid with the dose causing immunosuppressive (dose reference: equivalent to prednisone 20mg/day, more than one week); or monoclonal antibody ; or thymosin; or interferon, etc.; but local medication (such as ointment, eye drops, inhalation or nasal spray) is allowed.
- •Patients with active tuberculosis, viral hepatitis, human immunodeficiency virus or syphilis infection.
Outcomes
Primary Outcomes
Seroconvension of SARS-CoV-2 neutralizing antibodies
Time Frame: 14 days and 28 days after booster immunization
The seroconvension of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
GMT of SARS-CoV-2 neutralizing antibodies
Time Frame: 14 days and 28 days after booster immunization
The GMT of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
GMI of SARS-CoV-2 neutralizing antibodies
Time Frame: 14 days and 28 days after booster immunization
The GMI of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
Secondary Outcomes
- GMT of SARS-CoV-2 (wild type) neutralizing antibodies(Before and on day 7 after booster immunization)
- Seroconvension of SARS-CoV-2 (wild type) neutralizing antibodies(On day 7 after booster immunization)
- GMI of SARS-CoV-2 (wild type) neutralizing antibodies(On day 7 after booster immunization)
- GMT of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies(Before and on day 7, day 14, day 28 after booster immunization)
- Seroconvension of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies(On day 7, day 14, day 28 after booster immunization)
- Long-term immunity(6 months after booster immunization)
- Incidence of AEs(30 minutes, 0-7 days, 8-28 days after booster immunization, 12 months after booster immunization.)
- GMI of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies(On day 7, day 14, day 28 after booster immunization)